Vir Biotechnology
Market cap $1.58B 171.3M shares (10-Q, Oct 28, 2026) × $9.25 close Nov 17, 2026
Most recent annual filing: 2026-02-15
- VIR-5818 Ph1 readout2H 2026VIR-5818 Ph1 readout, 2H 2026, notable
- ECLIPSE 2 & 3 Ph31Q 2027ECLIPSE 2 & 3 Ph3, 1Q 2027, thesis-defining
- ECLIPSE 2 and 3 topline1Q 2027ECLIPSE 2 and 3 topline, 1Q 2027, material
- PRO-XTEN TCE preclinical programs corporateearly 2027PRO-XTEN TCE preclinical programs corporate, early 2027, routine
- ECLIPSE 2 / 3 corporate1Q 2027ECLIPSE 2 / 3 corporate, 1Q 2027, routine
- Oncology pipeline corporate update1Q 2027Oncology pipeline corporate update, 1Q 2027, routine
- CHD filing packageMid-2027CHD filing package, Mid-2027, notable
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (6 active programs)
VIR-5500
ASP6958VIR-5500
HIV bnAb
VIR-5818
- Undisclosed indication
VIR-5525
Technology platforms
dAIsY
Proprietary AI and machine learning-driven antibody optimization platform for engineering therapeutic candidates including TCEs and mAbs for infectious diseases and oncology. Used to optimize potency, resistance, pharmacokinetics, and manufacturability.
PRO-XTEN · Sanofi
Dual-masked T-cell engager platform using XTEN masking technology to keep TCEs inactive until reaching the tumor microenvironment, reducing off-target effects; focus on solid tumor indications including prostate cancer; licensed from Amunix Pharmaceuticals (a Sanofi company), with Vir retaining exclusive oncology and infectious disease rights
Targets: CD3, PSMA, HER2, EGFR
PRO-XTEN · Amunix Pharmaceuticals (a Sanofi company)
Universal dual-masking technology for T-cell engagers; designed to keep TCEs inactive until reaching the tumor microenvironment where tumor-specific proteases cleave the mask; focus areas: oncology solid tumors including prostate, HER2-expressing, and EGFR-expressing cancers; also licensed for infectious disease
Targets: PSMA, HER2, EGFR, CD3
PRO-XTEN · Amunix Pharmaceuticals (Sanofi)
Universal dual-masking technology for T-cell engagers (TCEs) that keeps TCEs inactive until tumor-specific proteases in the tumor microenvironment cleave the mask, activating anti-tumor killing; extends half-life and reduces systemic toxicity; applied across solid tumor indications targeting PSMA, HER2, and EGFR, as well as preclinical candidates in lung, colorectal, and bladder cancer; Vir Biotechnology holds exclusive rights for oncology and infectious disease
Targets: PSMA, CD3, HER2, EGFR
PRO-XTEN · Amunix Pharmaceuticals
Universal dual-masking technology for T-cell engagers (TCEs) that keeps TCEs inactive until reaching the tumor microenvironment, where tumor-specific proteases cleave the mask and activate the TCEs; applied across oncology solid tumor indications including prostate, HER2-positive, and EGFR-expressing tumors; licensed from Amunix Pharmaceuticals (a Sanofi company) with Vir holding exclusive rights for oncology and infectious disease
Targets: PSMA, HER2, EGFR, CD3
PRO-XTEN · Sanofi (via Amunix Pharmaceuticals)
Dual-masking platform technology that keeps T-cell engagers inactive until reaching the tumor microenvironment, reducing off-target effects and improving therapeutic index; focus on solid tumor indications and infectious diseases
PRO-XTEN · Amunix Pharmaceuticals, Inc. (a Sanofi company)
Universal dual-masking technology for T-cell engagers designed to extend half-life and keep TCEs inactive until reaching the tumor microenvironment, where tumor-specific proteases cleave the mask to activate anti-tumor activity; applied across solid tumor oncology and infectious disease indications.
Targets: PSMA, CD3
PRO-XTEN · Gilead Sciences
Universal masking technology for T-cell engagers (TCEs) — extends half-life and keeps TCEs inactive until reaching the tumor microenvironment, where tumor-specific proteases cleave the mask and activate anti-tumor activity; focus area: solid tumors and oncology broadly. Vir holds exclusive rights for oncology and infectious disease; technology owned by Amunix Pharmaceuticals (a Sanofi company).
PRO-XTEN · Gilead
Universal dual-masking T-cell engager platform; extends half-life and keeps TCEs inactive until tumor microenvironment proteases cleave the mask; focus areas: solid tumors and infectious disease oncology
Discontinued (1)
- tobevibart — Chronic Hepatitis B · decided not to pursue Phase 3 development of combinations of tobevibart and elebsiran in CHB
Capital (as filed)
- Cash
- $219M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $236M Sep 30, 2026
- Long-term investments
- $443M Sep 30, 2026
- Operating cash flow
- −$106M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $1.14B cash, runway mid-2027 per the update of Nov 13, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (12)
- 2026-11-14 UPDATE: Vir Biotechnology (VIR) - The $10 Print 🔒 Paid
- 2026-11-13 UPDATE: Vir Biotechnology (VIR) - The Post-Data Raise Arrives 🔒 Paid
- 2026-11-10 UPDATE: Vir Biotechnology (VIR) - THE BIG ONE Hits ★ Distilled Pro
- 2026-11-05 UPDATE: Vir Biotechnology (VIR) - The Platform Test Slips a Quarter ★ Distilled Pro
- 2026-10-15 UPDATE: Vir Biotechnology (VIR) - Gilead Buys a Ticket to the Trojan Horse ★ Distilled Pro
- 2026-10-08 UPDATE: Vir Biotechnology (VIR) - The CMO Chair Gets Filled, Too 🔒 Paid
- 2026-10-01 UPDATE: Vir Biotechnology (VIR) - The CFO Chair Gets Filled 🔒 Paid
- 2026-08-06 UPDATE: Vir Biotechnology (VIR) - Fully Enrolled, and the Competition Just Got Real 🔒 Paid
- 2026-07-24 UPDATE: Vir Biotechnology (VIR) - The CFO Walks, Too 🔒 Paid
- 2026-05-07 UPDATE: Vir Biotechnology (VIR) - The Clean Call (With a $172.5M Footnote) 🔒 Paid
- 2026-04-27 UPDATE: Vir Biotechnology (VIR) - The Astellas Money Lands, the CMO Walks 🔒 Paid
- 2026-03-25 Vir Biotechnology (VIR) - Scientific Deep Dive for Lead and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (12 calls)
Every verdict Biotech Distilled has published on Vir Biotechnology, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-03-25 Buy core Vir Biotechnology (VIR) - Scientific Deep Dive for Lead and Pipeline Products Fortified balance sheet, stellar Phase 2 CHD data, and a partnered PRO-XTEN oncology platform create highly asymmetric upside.
- 2026-04-27 Buy core UPDATE: Vir Biotechnology (VIR) - The Astellas Money Lands, the CMO Walks Astellas deal closed and balance sheet fortified, but CMO departure six months before ECLIPSE 1 warrants caution before adding aggressively.
- 2026-05-07 Buy core UPDATE: Vir Biotechnology (VIR) - The Clean Call (With a $172.5M Footnote) ECLIPSE timelines reaffirmed, CMO transition risk retired, fortress-level pro-forma cash; the wait-for-the-call condition is satisfied and adding is warranted.
- 2026-07-24 Buy core UPDATE: Vir Biotechnology (VIR) - The CFO Walks, Too Two C-suite departures in three months ahead of ECLIPSE 1 widen the yellow flag, but science and balance sheet are unchanged; existing holders should hold and new entrants should scale in rather than commit all at once.
- 2026-08-06 Buy core UPDATE: Vir Biotechnology (VIR) - Fully Enrolled, and the Competition Just Got Real Full ECLIPSE enrollment retires operational risk, fortress balance sheet intact, but FDA approval of a U.S. CHD competitor raises the commercial bar beyond just proving the drug works.
- 2026-10-01 Buy core UPDATE: Vir Biotechnology (VIR) - The CFO Chair Gets Filled Permanent outside CFO named before ECLIPSE 1, closing the C-suite turnover loop; thesis unchanged with fortified balance sheet and fully enrolled Phase 3.
- 2026-10-08 Buy core UPDATE: Vir Biotechnology (VIR) - The CMO Chair Gets Filled, Too Both C-suite vacancies filled with outside hires before ECLIPSE 1, fully resolving the turnover pattern; thesis intact heading into the binary readout.
- 2026-10-15 Buy core UPDATE: Vir Biotechnology (VIR) - Gilead Buys a Ticket to the Trojan Horse Gilead's $90M upfront at a 30% equity premium is a second big-pharma validation of the PRO-XTEN discovery engine, thickening the balance sheet ahead of ECLIPSE 1.
- 2026-11-05 Buy core UPDATE: Vir Biotechnology (VIR) - The Platform Test Slips a Quarter ECLIPSE 1 remains on track for Q4 and VIR-5500 gains Fast Track, but the HER2 platform-generalization readout has lost its 2H 2026 date after FDA dose-optimization feedback.
- 2026-11-10 Buy core UPDATE: Vir Biotechnology (VIR) - THE BIG ONE Hits ECLIPSE 1 met primary and key secondary endpoints decisively; CHD clinical risk largely retired, but commercial risk against an approved competitor remains and ECLIPSE 3 is the next key test.
- 2026-11-13 Buy core UPDATE: Vir Biotechnology (VIR) - The Post-Data Raise Arrives Post-ECLIPSE follow-on offering is real dilution but funds the commercial launch against bulevirtide without giving away rights; thesis intact with ECLIPSE 3 as the next test.
- 2026-11-14 Buy core UPDATE: Vir Biotechnology (VIR) - The $10 Print Offering priced at a steeper-than-expected 17.5% discount below the Astellas strike, but ~$1.1B pro-forma cash removes launch-financing overhang and the $10 print may set a near-term floor ahead of ECLIPSE 3.
- Long call · opened Mar 25, 2026 at $8.99 · +2.9% vs XBI +17.2% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (5 quotes from 3 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“Topline data from the pivotal ECLIPSE 1 trial are expected in the fourth quarter of 2026.”
matched to ECLIPSE 1 (tobevibart + elebsiran) · topline data
-
-
-
“These data, along with data from ECLIPSE 1 and 3, will be part of a comprehensive global filing package. ◦ Topline data from the Phase 3 ECLIPSE 1 trial are expected in the fourth quarter of 2026. ◦ Topline data from the ECLIPSE 2 and ECLIPSE 3 trials are expected in the first quarter of 2027.”
matched to ECLIPSE 1 (tobevibart + elebsiran) · topline data -
“We expect to report updated dose-escalation data from our Phase 1 trial evaluating VIR-5818, a HER2-targeted PRO-XTEN ® dual-masked TCE, as a monotherapy and in combination with pembrolizumab, in the second half of 2026.”
matched to VIR-5818 · readout other
-
-
-
“These data, along with data from ECLIPSE 1 and 3, will be part of a comprehensive global filing package. ◦ Topline data from the Phase 3 ECLIPSE 1 trial are expected in the fourth quarter of 2026. ◦ Topline data from the ECLIPSE 2 and ECLIPSE 3 trials are expected in the first quarter of 2027.”
matched to ECLIPSE 1 (tobevibart + elebsiran) · topline data -
“The Company expects to report updated dose-escalation data from its Phase 1 trial evaluating VIR-5818, a HER2-targeted PRO-XTEN ® dual-masked TCE, as a monotherapy and in combination with pembrolizumab, in the second half of 2026.”
matched to VIR-5818 · readout other
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (58)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 18, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 16, 20268-KCurrent report: material agreement, other events · EX-99.1
- Nov 16, 2026424B5Prospectus supplement (offering)
- Nov 16, 2026424B5Prospectus supplement (offering)
- Nov 12, 2026S-3ASRAutomatic shelf registration→ BD updateSummary on the 424B5
- Nov 12, 2026ReleaseVir Biotechnology Announces Proposed Public Offering→ BD updateSummary on the 424B5
- Nov 12, 2026424B5Prospectus supplement (offering)→ BD updateThree days after ECLIPSE 1 delivered its p<0.0001 verdict, Vir is raising capital in an underwritten public offering — the classic post-readout playbook, and a repeat of February's opportunistic raise into the Astellas pop. The stock bled 7.7% into today's close as the market digested the dilution; the offering terms land after the bell.
- Nov 9, 20268-KCurrent report: Reg FD disclosure, other events→ BD updateECLIPSE 1 met every endpoint: 79% of patients hit undetectable virus at Week 48 (p<0.0001), all 124 patients completed treatment, and exploratory data from SOLSTICE suggest 10/10 patients who stopped dosing after 96 weeks of viral suppression maintained sustained viral response — a potential cure signal for the most severe form of viral hepatitis.
- Nov 8, 2026ReleaseVir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis Delta→ BD updateSummary on the 8-K of Nov 9, 2026
- Nov 8, 2026ReleaseVir Biotechnology Announces Expanded Phase 2 SOLSTICE Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta, Showing Deep and Sustained Viral Suppression, and Exploratory Finite Treatment Data→ BD updateSummary on the 8-K of Nov 9, 2026
- Nov 6, 2026SCHEDULE 13D/A13D amendment
- Nov 5, 2026ReleaseVir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD’s The Liver Meeting® 2026 and Host Investor Conference Call
- Nov 4, 2026ReleaseVir Biotechnology Provides Corporate Update and Reports Third Quarter 2026 Financial Results→ BD updateSummary on the 8-K
- Nov 4, 20268-KCurrent report: results of operations · EX-99.1→ BD updateQ3 earnings land with ECLIPSE 1 now explicitly "this quarter," VIR-5500 earns FDA Fast Track and proof-of-concept status, and the VIR-5818 HER2 data timeline quietly slips on FDA Project Optimus feedback — the platform-generalization test just got delayed.
- Nov 4, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 2, 2026ReleaseVir Biotechnology to Participate in the Jefferies 2026 London Healthcare Conference
- Oct 28, 2026ReleaseVir Biotechnology Announces Appointment of Suzanne Topalian to its Board of Directors
- Oct 28, 20268-KCurrent report: officer / director change
- Oct 21, 2026ReleaseVir Biotechnology to Host Conference Call for Third Quarter 2026 Financial Results
- Oct 14, 2026ReleaseVir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors→ BD updateSummary on the 8-K
- Oct 14, 20268-KCurrent report: unregistered sale of equity, other events · EX-99.1→ BD updateGilead — the same company whose CHD drug competes with tobevibart + elebsiran — just paid $65M cash plus a $25M equity stake at a 30% premium to co-develop three new PRO-XTEN masked T-cell engagers for solid tumors, the second major validation of the platform in eight months. The stock fell anyway.
- Oct 8, 2026ReleaseVir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer
- Oct 8, 20268-KCurrent report: other events · EX-99.1
- Oct 7, 2026ReleaseVir Biotechnology Appoints David Liu as Chief Medical Officer→ BD updateThe last open C-suite gap is closed: Vir names David Liu, M.D., Ph.D. — a 25-year immuno-oncology veteran with a regulatory approval on his résumé — as CMO effective October 12, weeks before ECLIPSE 1 topline and completing the leadership rebuild I've been tracking since April.
- Oct 5, 2026ReleaseVir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD’s The Liver Meeting® 2026BD extracted 1 program update from this document → VIR pipeline
- Oct 1, 2026ReleaseVir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer→ BD updateSummary on the 8-K
- Oct 1, 20268-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1→ BD updateVir's permanent CFO search — the open loop I've flagged since July — just closed with a hire that has a specific edge: Aziz Sawaf comes from Gilead's R&D and commercial finance teams, meaning Vir's new finance chief built his career at the exact company whose drug now occupies the U.S. CHD market Vir intends to enter.
- Aug 31, 2026ReleaseVir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
- Aug 5, 2026ReleaseVir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer
- Aug 5, 2026ReleaseVir Biotechnology Announces Pricing of Public Offering of Common Stock
- Aug 5, 2026ReleaseVir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results
- Aug 5, 2026ReleaseVir Biotechnology Announces Proposed Public Offering of Common Stock
- Aug 5, 2026ReleaseVir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results
- Aug 5, 2026ReleaseVir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical MilestonesBD extracted 2 program updates from this document → VIR pipeline
- Aug 5, 2026ReleaseVir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference
- Aug 5, 2026ReleaseVir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results
- Aug 5, 2026ReleaseVir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
- Aug 5, 2026ReleaseAstellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer
- Aug 5, 2026ReleaseVir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference
- Aug 5, 2026ReleaseVir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial ResultsBD extracted 3 program updates from this document → VIR pipeline
- Aug 5, 20268-KCurrent report: results of operations · EX-99.1BD extracted 1 program update from this document → VIR pipeline
- Aug 5, 202610-QQuarterly report
- Jul 24, 2026ReleaseVir Biotechnology Announces Chief Financial Officer Transition
- Jul 24, 20268-KCurrent report: officer / director change
- Jul 22, 2026ReleaseVir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results
- Jun 10, 2026Release(Opens PDF Titled Vir Biotechnology To Present Complete Week 96 Data From Phase 2 SOLSTICE Clinical Trial In Hepatitis Delta At The European Association For The Study Of The Liver (EASL) Congress 2026BD extracted 1 program update from this document → VIR pipeline
- Jun 10, 2026ReleaseVir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors
- Jun 10, 20268-KCurrent report: officer / director change
- May 28, 20268-KCurrent report: officer / director change, shareholder vote
- May 18, 2026Release(Opens PDF Titled Vir Biotechnology Announces First Patient Dosed In Phase 1 Dose-Expansion Cohorts Evaluating PSMA-Targeted, PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 In Patients With Metastatic
- May 18, 2026ReleaseVir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026
- May 7, 202610-QQuarterly report
- May 6, 20268-KCurrent report: results of operations · EX-99.1
- Apr 16, 2026DEFA14AProxy soliciting material
- Apr 16, 2026DEF 14AProxy statement
- Apr 10, 20268-KCurrent report: officer / director change
- Mar 4, 20268-KCurrent report: officer / director change
- Mar 3, 2026SCHEDULE 13D/A13D amendment
- Mar 2, 20268-KCurrent report: other events
8 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 10, 2026SCHEDULE 13GPassive >5% holder (13G)
- Oct 27, 2026SCHEDULE 13G/A13G amendment
- Aug 7, 2026SCHEDULE 13GPassive >5% holder (13G)
- Jul 31, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13G/A13G amendment
- Apr 29, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 16, 2026ARSAnnual report to shareholders
- Mar 27, 2026SCHEDULE 13G/A13G amendment